PE20050439A1 - Forma de dosificacion farmaceutica de liberacion prolongada - Google Patents

Forma de dosificacion farmaceutica de liberacion prolongada

Info

Publication number
PE20050439A1
PE20050439A1 PE2004000984A PE2004000984A PE20050439A1 PE 20050439 A1 PE20050439 A1 PE 20050439A1 PE 2004000984 A PE2004000984 A PE 2004000984A PE 2004000984 A PE2004000984 A PE 2004000984A PE 20050439 A1 PE20050439 A1 PE 20050439A1
Authority
PE
Peru
Prior art keywords
substance
dosage form
gastrointestinal
soluble
active drug
Prior art date
Application number
PE2004000984A
Other languages
English (en)
Inventor
Nicholas Heaton
Angela Potts
Ian Armstrong
James Andrew Provost
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34354596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050439(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20050439A1 publication Critical patent/PE20050439A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA FORMA DE DOSIFICACION ORAL FARMACEUTICA O VETERINARIA PARA LA LIBERACION PROLONGADA DE UN FARMACO BIOLOGICAMENTE ACTIVO QUE ES SOLUBLE EN EL MEDIO GASTROINTESTINAL QUE COMPRENDE: a) UN NUCLEO SOLIDO FORMADO A PARTIR DE UNA FUSION O UNA MEZCLA DE UNA PRIMERA SUSTANCIA QUE ES ESENCIALMENTE INSOLUBLE EN EL MEDIO GASTROINTESTINAL Y QUE LLEVA EL FARMACO ACTIVO DISPERSADO Y b) UN REVESTIMIENTO APLICADO AL NUCLEO PROVENIENTE DE UNA SOLUCION , UNA DISPERSION, FUSION EN EL CUAL EL REVESTIMIENTO COMPRENDE UNA SEGUNDA SUSTANCIA QUE ES INSOLUBLE EN EL MEDIO GASTROINTESTINAL Y UN COMPONENTE SOLUBLE EN EL MEDIO GASTROINTESTINAL. SE REFIERE A UNA FORMA DE DOSIFICACION DONDE EL NUCLEO COMPRENDE ENTRE 25% A 75% (p/p) DE LA PRIMERA SUSTANCIA, ENTRE 0% Y 50% DE UN EXCIPIENTE QUE COMPRENDE UN DILUYENTE, AGENTE DE DESLIZAMIENTO, LUBRICANTE O CUALQUIER COMBINACION DE ESTOS. LA PRIMERA SUSTANCIA EN EL NUCLEO ES UNA CERA HIDROFOBICA Y LA SUSTANCIA DE REVESTIMIENTO ES UNA CERA HIDROFOBICA SELECCIONADA DE MONOESTEARATO DE GLICERILO, ALCOHOL CETOESTEARILICO, EL COMPONENTE SOLUBLE ES UN POLIETILENGLICOL Y EL COMPONENTE SOLUBLE EN EL REVESTIMIENTO ES UN FARMACO ACTIVO QUE ES IGUAL AL FARMACO DEL NUCLEO. EL FARMACO ACTIVO ES CLORHIDRATO DE VENLAFAXINA
PE2004000984A 2003-10-13 2004-10-12 Forma de dosificacion farmaceutica de liberacion prolongada PE20050439A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03256438A EP1523979A1 (en) 2003-10-13 2003-10-13 Extended release pharmaceutical dosage form

Publications (1)

Publication Number Publication Date
PE20050439A1 true PE20050439A1 (es) 2005-08-03

Family

ID=34354596

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000984A PE20050439A1 (es) 2003-10-13 2004-10-12 Forma de dosificacion farmaceutica de liberacion prolongada

Country Status (14)

Country Link
US (1) US20050129762A1 (es)
EP (2) EP1523979A1 (es)
KR (1) KR20060108675A (es)
CN (1) CN1889935A (es)
AR (1) AR046102A1 (es)
AU (1) AU2004283436A1 (es)
CA (1) CA2546199A1 (es)
CO (1) CO5690532A2 (es)
CR (1) CR8403A (es)
EC (1) ECSP066566A (es)
NO (1) NO20062142L (es)
PE (1) PE20050439A1 (es)
TW (1) TW200518788A (es)
WO (1) WO2005039527A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
EP1830886B1 (en) * 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
JP5290198B2 (ja) * 2006-12-20 2013-09-18 ミラン ファーマシューティカルズ ユーエルシー ホットメルト顆粒化潤滑剤を含んでなる医薬組成物
AU2014201170B2 (en) * 2006-12-20 2015-09-24 Mylan Pharmaceuticals Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
US8178118B2 (en) 2007-03-22 2012-05-15 Magceutics, Inc. Magnesium compositions and uses thereof for cognitive function
KR101758624B1 (ko) 2007-03-22 2017-07-14 뉴로센트리아, 인크. 마그네슘 조성물 및 이의 용도
EP2448413A4 (en) * 2009-07-01 2013-02-13 Magceutics Inc SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556141A (es) * 1956-03-27
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US20030059466A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Delayed release tablet of venlafaxin
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AU2003226752A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine base
WO2003082261A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Extended release venlafaxine formulations
IL149055A0 (en) * 2002-04-09 2002-11-10 Karma Pharm Ltd Extended release composition comprising as active compound venlafaxine hydrochloride
WO2005009412A1 (en) * 2003-07-24 2005-02-03 Wockhardt Limited Oral compositions for treatment of diseases

Also Published As

Publication number Publication date
WO2005039527A2 (en) 2005-05-06
CR8403A (es) 2006-10-26
US20050129762A1 (en) 2005-06-16
EP1523979A1 (en) 2005-04-20
CA2546199A1 (en) 2005-05-06
CO5690532A2 (es) 2006-10-31
NO20062142L (no) 2006-07-06
WO2005039527A3 (en) 2006-04-06
AR046102A1 (es) 2005-11-23
KR20060108675A (ko) 2006-10-18
ECSP066566A (es) 2006-10-17
TW200518788A (en) 2005-06-16
AU2004283436A1 (en) 2005-05-06
EP1675575A2 (en) 2006-07-05
CN1889935A (zh) 2007-01-03

Similar Documents

Publication Publication Date Title
ES2526092T3 (es) Formulaciones de olanzapina en nanopartículas inyectables
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
CO6150127A2 (es) Formulaciones de flibanserina y metodo para fabricarlas
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
BRPI0414017A8 (pt) pró-fármacos poliméricos de múltiplos braços
EP1993567A4 (en) PER OS ADMINISTRABLE GALLIUM PREPARATIONS AND METHODS OF USE
AR045068A1 (es) Formulacion de liberacion inmediata de composiciones farmaceuticas
BRPI0716436B8 (pt) sistema de liberação controlada e método para fabricação do mesmo
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
ATE457719T2 (de) Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel
AR069905A1 (es) Formulacion de liberacion controlada, preventiva de mal uso, en donde el agente farmaceuticamente activo es un farmaco con capacidad de abuso
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
WO2005072343A3 (en) Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use
CR10404A (es) Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente
ECSP088165A (es) Formulaciones liquidas
CY1118057T1 (el) Φαρμακευτικη συνθεση για στοματικη χορηγηση
CO5060477A1 (es) Forma de dosificacion de nefazodona
PE20050439A1 (es) Forma de dosificacion farmaceutica de liberacion prolongada
MX2010005013A (es) Composiciones intranasales.
ECSP099439A (es) Composición de liberación sostenida y métodos para producirla
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
BRPI0412458A (pt) composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride

Legal Events

Date Code Title Description
FC Refusal